Page 19 - Compass Pathways News Today

Private psychedelics companies have raised hundreds of millions of dollars. Here are the biggest venture investors backing their efforts.

Author summary Why was this study done? Patients with severe mental illness (SMI) have been reported to have excess mortality from sepsis (number of deaths due to sepsis in the whole population). Whether SMI is associated with higher or lower sepsis-associated case fatality remains unclear (number of deaths due to sepsis in the population with sepsis). No study has determined whether SMI is associated with excess case fatality in patients with septic shock, the most severe form of sepsis when ...

In this article, we discuss 10 best psychedelic stocks to buy according to hedge funds.

Neither is profitable, but both could be on the verge of massive booms in revenue.

Investing now is an admittedly risky bet, but the payoff could be massive.

COMPASS Pathways plc (NASDAQ:CMPS – Get Rating) – Equities research analysts at Oppenheimer decreased their Q1 2023 earnings per share (EPS) estimates for COMPASS Pathways in a note issued to investors on Tuesday, February 28th. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings of ($0.68) per share for the quarter, down […]

CMPS earnings call for the period ending December 31, 2022.

Adding simvastatin to standard therapy offers no benefit over placebo for treatment-resistant depression, a new randomized clinical trial shows.

Compass Pathways is running a massive clinical trial that will likely help it turn a psychedelic substance into an approved medicine.

These stocks are risky. But they just might deliver huge gains if analysts are right.